139 related articles for article (PubMed ID: 18092329)
21. TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.
Mahner S; Woelber L; Eulenburg C; Schwarz J; Carney W; Jaenicke F; Milde-Langosch K; Mueller V
BMC Cancer; 2010 Apr; 10():139. PubMed ID: 20388222
[TBL] [Abstract][Full Text] [Related]
22. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
23. Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma.
Chen W; Shan B; Zhou S; Yang H; Ye S
BMC Cancer; 2022 Jan; 22(1):92. PubMed ID: 35062908
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study.
Riedinger JM; Eche N; Basuyau JP; Dalifard I; Hacene K; Pichon MF
Gynecol Oncol; 2008 May; 109(2):194-8. PubMed ID: 18329083
[TBL] [Abstract][Full Text] [Related]
25. Maintenance or consolidation therapy in advanced ovarian cancer.
Pectasides D; Pectasides E
Oncology; 2006; 70(5):315-24. PubMed ID: 17164587
[TBL] [Abstract][Full Text] [Related]
26. Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125).
Gronlund B; Høgdall EV; Christensen IJ; Johansen JS; Nørgaard-Pedersen B; Engelholm SA; Høgdall C
Int J Biol Markers; 2006; 21(3):141-8. PubMed ID: 17013795
[TBL] [Abstract][Full Text] [Related]
27. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
[TBL] [Abstract][Full Text] [Related]
28. Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer.
Mathey S; Graeser MK; Zu Eulenburg C; Woelber L; Trillsch F; Jaenicke F; Müller V; Milde-Langosch K; Mahner S
Oncology; 2013; 85(2):69-77. PubMed ID: 23860180
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
Tropé CG; Elstrand MB; Sandstad B; Davidson B; Oksefjell H
Eur J Cancer; 2012 Sep; 48(14):2146-54. PubMed ID: 22382201
[TBL] [Abstract][Full Text] [Related]
30. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
Gadducci A; Zola P; Landoni F; Maggino T; Sartori E; Bergamino T; Cristofani R
Gynecol Oncol; 1995 Jul; 58(1):42-7. PubMed ID: 7789889
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
[TBL] [Abstract][Full Text] [Related]
32. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
[TBL] [Abstract][Full Text] [Related]
33. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?
Gronlund B; Høgdall C; Hilden J; Engelholm SA; Høgdall EV; Hansen HH
J Clin Oncol; 2004 Oct; 22(20):4051-8. PubMed ID: 15364966
[TBL] [Abstract][Full Text] [Related]
34. Expression of the major fas family and Bcl-2 family of proteins in epithelial ovarian cancer (EOC) and their correlation to chemotherapeutic response and outcome.
Chaudhry P; Srinivasan R; Patel FD
Oncol Res; 2010; 18(11-12):549-59. PubMed ID: 20939431
[TBL] [Abstract][Full Text] [Related]
35. Monitoring cancer antigen 125 levels in induction chemotherapy for epithelial ovarian carcinoma and predicting outcome of second-look procedure.
Folk JJ; Botsford M; Musa AG
Gynecol Oncol; 1995 May; 57(2):178-82. PubMed ID: 7729730
[TBL] [Abstract][Full Text] [Related]
36. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
37. Utility of gene promoter methylation in prediction of response to platinum-based chemotherapy in epithelial ovarian cancer (EOC).
Chaudhry P; Srinivasan R; Patel FD
Cancer Invest; 2009 Oct; 27(8):877-84. PubMed ID: 19548140
[TBL] [Abstract][Full Text] [Related]
38. Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer.
Wang Y; Liu P; Xu Y; Zhang W; Tong L; Guo Z; Ni H
Cancer Chemother Pharmacol; 2015 Feb; 75(2):255-62. PubMed ID: 25428515
[TBL] [Abstract][Full Text] [Related]
39. Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients.
Yin JY; Li X; Li XP; Xiao L; Zheng W; Chen J; Mao CX; Fang C; Cui JJ; Guo CX; Zhang W; Gao Y; Zhang CF; Chen ZH; Zhou H; Zhou HH; Liu ZQ
Cancer Lett; 2016 Jul; 377(1):65-73. PubMed ID: 27126360
[TBL] [Abstract][Full Text] [Related]
40. Apoptosis markers soluble Fas (sFas), Fas Ligand (FasL) and sFas/FasL ratio in patients with bacteremia: a prospective cohort study.
Huttunen R; Syrjänen J; Vuento R; Laine J; Hurme M; Aittoniemi J
J Infect; 2012 Mar; 64(3):276-81. PubMed ID: 22207003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
